View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris TORONTO and EDMONTON, Alberta, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”). The parties anticipate completing the Transaction i...

 PRESS RELEASE

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris

Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris TORONTO and EDMONTON, March 28, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna") and Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro”) are pleased to announce that the Court of King's Bench of Alberta has issued a final order approving the arrangement described in the previously announced definitive agreement to combine the operations of Ceapro and Aeterna in an all-stock merger of equals transaction (the “Transaction”). The parties anticipate completing the Transaction in the sec...

 PRESS RELEASE

Form 8.3 - ABRDN European Logistics Income PLC

Form 8.3 - ABRDN European Logistics Income PLC 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Rathbones Group Plc(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant securitie...

LX International Corp: 3 directors

Three Directors at LX International Corp bought/maiden bought 6,145 shares at between 25,876.000KRW and 26,367.000KRW. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all th...

 PRESS RELEASE

HEALWELL AI Reports Q4 and Full Year 2023 Financial Results

HEALWELL AI Reports Q4 and Full Year 2023 Financial Results HEALWELL AI achieved annual revenue from continuing operations of $7.32 million in fiscal 2023. HEALWELL ended 2023 with a strong balance sheet, having secured approximately $29.5 million from convertible debt and equity financings.Since its relaunch in Q4 2023, the Company’s annual revenue run rate has more than doubled to over $20M with the largest component of revenues now coming from SaaS and services.Management provides a positive outlook based on strong and active acquisition and business development pipeline with the potenti...

 PRESS RELEASE

CAPREIT Announces $216MM in Strategic Transactions

CAPREIT Announces $216MM in Strategic Transactions TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Canadian Apartment Properties Real Estate Investment Trust (“CAPREIT”) (TSX:CAR.UN) announced today that it has closed on four non-core Canadian dispositions for combined consideration of $83.5 million, and has entered into an agreement to dispose of an additional parcel of unused land for $2.0 million. CAPREIT has also completed the acquisition of two strategically aligned, newly constructed purpose-built rental properties in Canada for $130.0 million. All amounts disclosed herein exclude trans...

 PRESS RELEASE

EQS-News: Biotest AG steigert den Umsatz um 32% im Geschäftsjahr 2023

EQS-News: Biotest AG / Schlagwort(e): Jahresergebnis Biotest AG steigert den Umsatz um 32% im Geschäftsjahr 2023 28.03.2024 / 12:38 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG   Biotest AG steigert den Umsatz um 32% im Geschäftsjahr 2023   EBIT Prognose mit einem EBIT von 143 Mio. € erreicht Zulassungsantrag Yimmugo bei der US amerikanischen Behörde FDA eingereicht Phase III Studie mit Fibrinogen erfolgreich   Dreieich, 28. März 2024. Die Biotest Gruppe erwirtschaftete im Berichtsjahr 2023 Umsatzerlöse in H...

 PRESS RELEASE

EQS-News: Biotest AG increased sales by 32% in the financial year 2023

EQS-News: Biotest AG / Key word(s): Annual Results Biotest AG increased sales by 32% in the financial year 2023 28.03.2024 / 12:38 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE   Biotest AG increased sales by 32% in the financial year 2023   EBIT forecast achieved with EBIT of € 143 million Yimmugo marketing authorization application submitted to the US FDA Phase III study with fibrinogen successful Dreieich, 28 March 2024. In the financial year 2023, the Biotest Group generated revenue of € 684.6 million compared wit...

Dan Salmon
  • Dan Salmon

Amazon.com (AMZN, Buy, $224 target) Breaking out AWS Generative AI Re...

We believe re-acceleration of AWS revenue growth is the most likely driver of upside in AMZN shares in 2024, as improved Retail profitability is increasingly baked into the stock. With customer optimizations abating, we expect Gen AI services to increasingly drive revenue growth.

Nawi Brothers Group Limited: 1 director

A director at Nawi Brothers Group Limited bought 3,401,682 shares at 26.500ILS and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...

Vimian Group AB: 1 director

A director at Vimian Group AB bought 20,000 shares at 29.304SEK and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...

Luminor Bank AS: Key facts and statistics - 2023

A summary company profile, detailing Luminor Bank AS’ business operations and financial highlights.

 PRESS RELEASE

Philip Morris International Demonstrates Clear Progress Toward Its Pur...

STAMFORD, CT--(BUSINESS WIRE)-- Philip Morris International Inc. (PMI) (NYSE: PM) today releases its fifth annual Integrated Report, which outlines the company’s ongoing work to advance toward its 2025 Roadmap goals, with the primary focus on addressing the health impacts of the company’s products. The 2023 Integrated Report highlights PMI’s continued expansion of smoke-free alternatives in markets worldwide, as well as social and environmental programs deployed with and in parallel to these products—including the deployment of responsible marketing and sales practices and efforts to reduce ...

 PRESS RELEASE

Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financ...

Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. Fourth Quarter and Recent Highlights The pivotal STRIDE study of mavodelpar in adult patients with primary mitochond...

Paolo Pizzoli
  • Paolo Pizzoli

Italian business confidence improves in March as consumers take a brea...

Overall this is a positive reading, marking an improvement among manufacturers and a surprising resilience among builders. Consumers are taking a breather, showing tentative concerns about future unemployment for the first time in months

 PRESS RELEASE

Hudbay Provides Annual Reserve and Resource Update and Production Outl...

Hudbay Provides Annual Reserve and Resource Update and Production Outlook Consolidated copper production is expected to average 153,000i tonnes per year over the next three years, representing a 16% increase from 2023 and demonstrating Hudbay’s strong and stable operating portfolio with three long-life operations in tier-one mining jurisdictions in the Americas. Strong complementary gold exposure with consolidated gold production expected to average 272,500i ounces per year over the next three years, reflecting strong production in Manitoba and a contribution from Pampacancha high grade gol...

 PRESS RELEASE

Perspective Therapeutics Provides Recent Business Highlights and Repor...

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023.  “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therap...

 PRESS RELEASE

Theratechnologies présentera au congrès de l’AACR des données préclini...

Theratechnologies présentera au congrès de l’AACR des données précliniques sur plusieurs conjugués peptide-médicament illustrant le potentiel de sa plateforme technologique SORT1+(MC) Une étude permettra d’évaluer de nouveaux conjugués camptothécine-peptide pour le traitement des cancers colorectaux exprimant la sortilineDes données distinctes mettent en évidence l’activité du sudocétaxel zendusortide (TH1902) pour activer la voie cGAS-STING et potentialiser la destruction de cellules tumorales par immunothérapie anti-PD-L1 MONTRÉAL, 28 mars 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc...

 PRESS RELEASE

Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financ...

Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results 2023 OvaSuite revenue of $9.2 million, an increase of 15% year-over-year 2023 OvaSuite volume of 23,990 units, an increase of 12% year-over-year Cash utilization declined in both the fourth quarter and full-year 2023 to $3.5 million and $15.9 million, respectively Conference Call and Webcast scheduled for today at 8:30 am ET AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused ...

 PRESS RELEASE

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2...

Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call Call Scheduled for Today, Thursday, March 28, 2024 at 5:00 pm ET LITTLETON, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults)), today announced it plans to release its f...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch